Subscribe

Dr. Lal PathLabs Limited (LALPATHLAB.NS)

INR1,744.60 +19.50 (+1.13%)
IN NSE Healthcare Medical - Diagnostics & Research
Address Tower B, SAS Tower 122001
Gurugram, IN
CEO Shankha Banerjee
Website lalpathlabs.com
IPO 2015-12-23
ISIN INE600L01024

Explore sections of this company profile

Also trades on Bombay Stock Exchange · LALPATHLAB.BO (INR) National Stock Exchange of India · LALPATHLAB.NS (INR)
Description

Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR1,744.60 +19.50 (+1.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
622.5K
Beta
0.19
Float Shares
149.92M
Free Float %
89.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.84% +2.72% +15.99% +14.42% +1.82% +7.95% +15.14% +59.33% +17.70% +235.92% +287.98%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1,744.60
DCF (Unlevered) 3,339.96 +91.4%
DCF (Levered) 3,366.70 +93.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 75% Bullish
Rating 2026-05 Change
Strong Buy 5 0
Buy 13 0
Hold 2 -1
Sell 2 0
Strong Sell 2 0
Quality scores
Altman Z-Score
28.30
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Diagnostics & Research: +7.9%
    +12.3% ★ Q1'26: +16.6% (vs Q1'25)
  • ✓
    EPS growth Medical - Diagnostics & Research: +30.8%
    +3.4% Q1'26: -15.4% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%
    +16.8% Q1'26: +27.0% (vs Q1'25)
  • ✓
    EBIT margin Medical - Diagnostics & Research: +9.6%
    +22.5% ★ Q1'26: +20.2% (vs Q1'25)
  • ✓
    ROIC Medical - Diagnostics & Research: +5.2%
    +33.6% ★ Q1'26: +33.4% (vs Q1'25)
  • ✗
    Share dilution Medical - Diagnostics & Research: 0.0%
    +0.2% Q1'26: +0.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×
    0.25× ★ Q1'26: 0.27× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.11) × ERP
WACC = 99% × Ke + 1% × Kd (11.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 3,179.51 Current price: 1,744.60
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
23 Rev. Ana.
18 EPS Ana. 		Mar 2027
26 Rev. Ana.
24 EPS Ana. 		Mar 2028
26 Rev. Ana.
24 EPS Ana. 		Mar 2029
10 Rev. Ana.
9 EPS Ana.
Revenue
7.91B
est: 7.87B (+0.5%)
9.12B
est: 9.27B (-1.6%)
10.57B
est: 10.51B (+0.6%)
12.03B
est: 12.13B (-0.8%)
13.30B
est: 13.59B (-2.1%)
15.81B
est: 15.68B (+0.9%)
20.87B
est: 21.23B (-1.7%)
20.17B
est: 20.49B (-1.6%)
22.27B
est: 22.88B (-2.7%)
24.61B
est: 24.68B (-0.3%)
27.34B
27.20B – 27.69B
+10.8% YoY
31.26B
30.92B – 31.56B
+14.3% YoY
35.24B
34.47B – 36.07B
+12.7% YoY
39.36B
39.33B – 39.40B
+11.7% YoY
EBITDA
2.29B
est: 1.95B (+17.4%)
2.65B
est: 2.91B (-9.0%)
2.95B
est: 3.27B (-9.6%)
3.40B
est: 3.74B (-9.1%)
3.99B
est: 4.29B (-7.1%)
4.88B
est: 4.30B (+13.3%)
6.13B
est: 5.21B (+17.7%)
5.32B
est: 5.78B (-8.0%)
6.78B
est: 6.71B (+1.1%)
7.89B
est: 7.27B (+8.5%)
8.01B
7.97B – 8.12B
+10.2% YoY
9.16B
9.06B – 9.25B
+14.3% YoY
10.33B
10.10B – 10.57B
+12.7% YoY
11.54B
11.53B – 11.55B
+11.7% YoY
EBIT
2.01B
est: 1.66B (+21.6%)
2.38B
est: 2.15B (+10.7%)
2.62B
est: 2.37B (+10.5%)
3.01B
est: 2.67B (+12.9%)
3.26B
est: 2.87B (+13.5%)
4.10B
est: 2.77B (+48.1%)
5.05B
est: 3.35B (+50.6%)
3.81B
est: 3.72B (+2.5%)
5.35B
est: 5.30B (+0.9%)
6.47B
est: 5.75B (+12.5%)
6.34B
6.30B – 6.42B
+10.2% YoY
7.24B
7.17B – 7.32B
+14.3% YoY
8.17B
7.99B – 8.36B
+12.7% YoY
9.12B
9.11B – 9.13B
+11.7% YoY
Net Income
1.32B
est: 1.31B (+0.7%)
1.55B
est: 1.56B (-1.1%)
1.71B
est: 1.74B (-2.1%)
1.99B
est: 1.97B (+0.9%)
2.26B
est: 2.24B (+1.0%)
2.92B
est: 2.31B (+26.2%)
3.45B
est: 2.80B (+23.2%)
2.39B
est: 3.10B (-23.0%)
3.58B
est: 7.67B (-53.4%)
4.87B
est: 4.35B (+12.0%)
5.05B
4.74B – 5.38B
+16.0% YoY
5.91B
5.56B – 6.33B
+17.0% YoY
6.89B
6.19B – 7.38B
+16.6% YoY
7.77B
7.30B – 8.46B
+12.7% YoY
SGA
580.28M
est: 1.37B (-57.7%)
1.69B
est: 4.45B (-61.9%)
2.10B
est: 5.01B (-58.0%)
2.34B
est: 6.10B (-61.6%)
2.22B
est: 6.78B (-67.2%)
2.50B
est: 6.58B (-62.0%)
3.48B
est: 7.97B (-56.3%)
3.58B
est: 8.83B (-59.5%)
4.15B
est: 4.16B (-0.3%)
4.51B
est: 4.51B (+0.0%)
4.97B
4.95B – 5.03B
+10.2% YoY
5.68B
5.62B – 5.74B
+14.3% YoY
6.41B
6.27B – 6.56B
+12.7% YoY
7.16B
7.15B – 7.16B
+11.7% YoY
EPS
8.05
est: 15.74 (-48.9%)
9.51
est: 19.41 (-51.0%)
10.43
est: 20.83 (-49.9%)
12.10
est: 24.31 (-50.2%)
13.71
est: 30.61 (-55.2%)
17.67
est: 34.25 (-48.4%)
20.85
est: 45.89 (-54.6%)
14.41
est: 30.88 (-53.3%)
21.53
est: 45.89 (-53.1%)
29.24
est: 26.02 (+12.4%)
30.57
28.36 – 32.18
+17.5% YoY
35.21
33.28 – 37.87
+15.2% YoY
40.80
37.04 – 44.17
+15.9% YoY
47.52
43.65 – 50.62
+16.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 A- 4/5 5/5 5/5 5/5 3/5 1/5 1/5
2026-05-11 A- 4/5 5/5 5/5 5/5 3/5 1/5 1/5
2026-05-08 A- 4/5 5/5 5/5 5/5 3/5 1/5 1/5
2026-05-07 A- 4/5 5/5 5/5 5/5 3/5 1/5 1/5
2026-05-06 B+ 3/5 3/5 5/5 5/5 3/5 1/5 1/5
2026-05-05 B+ 3/5 3/5 5/5 5/5 3/5 1/5 1/5
2026-05-04 B+ 3/5 3/5 5/5 5/5 3/5 1/5 1/5
2026-04-30 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-15 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
432.42M
OE per share TTM
2.59
Owner's Yield
0.16%
Maintenance CapEx ratio
9.39%
Maint CapEx / Avg PPE
18.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.51M
Shares Outstanding
166.97M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Brigadier Arvind Lal Executive Chairman 32M —
Vandana Lal Whole-Time Director 26M —
Ved Prakash Goel Group Chief Financial Officer & Chief Executive Officer of International Business 7M male
Munender Soperna Group Chief Information & Digital Officer — male
Shankha Banerjee Chief Executive Officer — male
Vinay Gujral Company Secretary & Compliance Officer — male
Jai Prakash Meena Chief Operating Officer — male
Manoj Kumar Garg Group Chief Human Resources Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Diagnostics & Research